A pharmaceutical composition for the treatment of pain in human patients wherein said composition comprises buprenorphine to naloxone in a ratio by weight of from 2.1:1 to 8:1. The amount of buprenorphine and naloxone is suitable to provide analgesia, the composition being in a transdermal or transmucosal dosage form. Also provided are an associated, method and use.